Net product sales increased 28% over third quarter 2006 to $177
million SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today reported financial
results for the quarter ended September 30, 2007. The Company
reported total revenue of $190.0 million for the third quarter,
including net product sales of $177.4 million. Net loss for the
quarter ended September 30, 2007 was $39.8 million, or $0.30 per
share. At September 30, 2007, the Company held cash, cash
equivalents and short-term investments of approximately $1.1
billion. "BYETTA and SYMLIN, our first-in-class diabetes medicines,
have been on the market for nearly 30 months and continued to show
growth in physician adoption, prescriptions and reported revenue in
the third quarter," said Daniel M. Bradbury, President and Chief
Executive Officer of Amylin Pharmaceuticals. "Additionally we
continued to advance our pipeline drug candidates and remain on
track to report key clinical data later this quarter from our
once-weekly exenatide long-acting release program and our
integrated neurohormone obesity program." Quarter ended September
30, 2007 Net product sales of $177.4 million for the third quarter
include $161.1 million for BYETTA(R) (exenatide) injection and
$16.3 million for SYMLIN(R) (pramlintide acetate) injection. This
compares to net product sales of $138.8 million, consisting of
$126.4 million for BYETTA and $12.4 million for SYMLIN for the same
period in 2006. Revenues under collaborative agreements were $12.6
million for the quarter ended September 30, 2007, compared to $8.2
million for the same period in 2006. The increase reflects higher
cost-sharing payments from Lilly to equalize development expenses
for BYETTA and exenatide long-acting release (LAR). Selling,
general and administrative expenses increased to $87.7 million for
the quarter ended September 30, 2007, compared to $69.0 million for
the same period in 2006. The increase reflects higher promotional
expenses for BYETTA and SYMLIN, increased expenses associated with
the Company's expanded field force, and increased business
infrastructure to support the Company's growth. Research and
development expenses increased to $61.5 million for the quarter
ended September 30, 2007, compared to $53.7 million for the same
period in 2006. The increase primarily reflects increased
development expenses for exenatide LAR and ongoing costs associated
with the advancement of the Company's obesity development programs.
Collaborative profit sharing, which represents Lilly's share of the
gross margin for BYETTA, was $75.0 million for the quarter ended
September 30, 2007, compared to $57.0 million for the same period
in 2006. Net loss for the quarter ended September 30, 2007 was
$39.8 million, or $0.30 per share, compared to $46.1 million, or
$0.36 per share, for the same period in 2006. Net loss for the
quarter ended September 30, 2006 included a $7.9 million
non-operating charge related to a make-whole payment associated
with the early redemption of convertible senior debt in August
2006. Third quarter highlights Highlights of Amylin's third quarter
include: -- Received U.S. Food and Drug Administration (FDA)
approval of the SymlinPen(TM) 120 and the SymlinPen(TM) 60
pen-injector devices for administering SYMLIN(R) (pramlintide
acetate) injection. These new pre-filled pen-injector devices
feature simple, fixed dosing to improve mealtime glucose control.
-- Announced study results showing that with similar glycemic
improvement, one year of exenatide treatment improved indices of
beta cell function compared to insulin glargine, with reduced risk
of hypoglycemia, and weight loss instead of weight gain. Nine
months ended September 30, 2007 Total revenues for the nine months
ended September 30, 2007 were $559.0 million. This includes net
product sales of $506.7 million, including $459.7 million for
BYETTA and $47.0 million for SYMLIN. This compares to net product
sales of $323.5 million, consisting of $293.2 million for BYETTA
and $30.3 million for SYMLIN for the same period in 2006. Revenues
under collaborative agreements were $52.2 million for the nine
months ended September 30, 2007, compared to $24.1 million for the
same period in 2006. The increase reflects $15 million in
milestones associated primarily with the launch of BYETTA in the
European Union during the second quarter of 2007 and higher
cost-sharing payments to equalize development expenses for BYETTA
and exenatide LAR. Selling, general and administrative expenses
increased to $268.6 million for the nine months ended September 30,
2007, from $192.4 million for the same period in 2006. The increase
reflects higher promotional expenses for BYETTA and SYMLIN, costs
associated with the Company's expanded sales force and increased
business infrastructure to support the Company's growth. Research
and development expenses increased to $192.7 million for the nine
months ended September 30, 2007, from $155.9 million for the same
period in 2006. The increase primarily reflects costs associated
with the development of exenatide LAR and costs associated with the
Company's obesity programs. Collaborative profit sharing was $212.3
million for the nine months ended September 30, 2007, compared to
$130.4 million for the same period in 2006. Net loss was $134.2
million, or $1.02 per share for the nine months ended September 30,
2007, compared to $160.4 million, or $1.33 per share, for the same
period in 2006. Conference Call Amylin will webcast its Quarterly
Update Conference Call today at 5:00 p.m. ET/2:00 p.m. PT. The call
will be webcast live through Amylin's corporate website,
http://www.amylin.com/, and a recording will be made available
following the close of the call. Daniel M. Bradbury, Amylin's
President and Chief Executive Officer will lead the call. During
the call, the Company plans to provide further details underlying
its third quarter financial results, and information regarding
assumptions for the remainder of 2007 operations. For those without
access to the Internet, the live call may be accessed by phone by
calling (866) 700-6979 (domestic) or (617) 213-8836
(international), passcode 48312438. A replay of the call will also
be available by phone for 24 hours beginning approximately one hour
after the close of the call and can be accessed at (888) 286-8010
(domestic) or (617) 801-6888 (international), passcode 10940869.
About Amylin Amylin Pharmaceuticals is a biopharmaceutical company
committed to improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is located in San
Diego, California with over 1,800 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. This press release contains forward-looking
statements about Amylin, which involve risks and uncertainties. The
Company's actual results could differ materially from those
discussed herein due to a number of risks and uncertainties,
including risks that BYETTA or SYMLIN may be affected by
competition, unexpected new data, technical issues, or
manufacturing and supply issues; risks that our financial results
may fluctuate significantly from period to period and may not meet
market expectations; risks that our clinical trials will not be
completed when planned or may not replicate previous results; risks
that our preclinical studies may not be predictive; risks that the
FDA may not approve the Company's sNDAs or product candidates;
risks that we may not be able to complete our manufacturing
facility on a timely basis; and other risks inherent in the drug
development and commercialization process. Commercial and
government reimbursement and pricing decisions and the pace of
market acceptance may also affect the potential for BYETTA or
SYMLIN. These and additional risks and uncertainties are described
more fully in the Company's recently filed Form 10-Q. Amylin
disclaims any obligation to update these forward-looking
statements. (Financial information to follow) AMYLIN
PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in
thousands, except per share data) (unaudited) Quarter ended Nine
months ended September 30, September 30, 2007 2006 2007 2006
Revenues: Net product sales $177,391 $138,798 $506,731 $323,457
Revenues under collaborative agreements 12,637 8,219 52,228 24,055
Total revenues 190,028 147,017 558,959 347,512 Costs and expenses:
Cost of goods sold 13,750 14,508 43,322 38,937 Selling, general and
administrative 87,718 69,037 268,626 192,388 Research and
development 61,457 53,703 192,712 155,886 Collaborative profit
sharing 75,026 57,026 212,328 130,382 Total costs and expenses
237,951 194,274 716,988 517,593 Operating loss (47,923) (47,257)
(158,029) (170,081) Make-whole payment on debt redemption - (7,875)
- (7,875) Interest income, net 8,165 8,992 23,834 17,521 Net loss
$(39,758) $(46,140) $(134,195) $(160,435) Net loss per share -
basic and diluted $(0.30) $(0.36) $(1.02) $(1.33) Shares used in
computing net loss per share - basic and diluted 132,805 126,582
131,884 120,423 AMYLIN PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED
BALANCE SHEETS (in thousands) (unaudited) September 30, December
31, 2007 2006 Assets Cash, cash equivalents and short-term
investments $1,082,478 $767,331 Accounts receivable, net 63,155
58,089 Inventories, net 103,480 59,299 Other current assets 32,223
22,098 Property and equipment, net 335,563 146,779 Other assets
33,816 6,790 Total assets $1,650,715 $1,060,386 Liabilities and
stockholders' equity Current liabilities $229,999 $203,887 Other
liabilities, net of current portion 33,293 21,208 Convertible
senior notes 775,000 200,000 Stockholders' equity 612,423 635,291
Total liabilities and stockholders' equity $1,650,715 $1,060,386
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark Foletta,
Senior Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024